Multiple Myeloma Market research report has been prepared with the systematic gathering and evaluation of market information for industry which is presented in a form that explains various facts and figures to the business. Report saves valuable time as well as adds credibility to the work that is performed to grow business. This quality report has been planned with full commitment and transparency in research and analysis. With the systematic insights of this report, companies can self-assuredly take decisions about the production and marketing strategies. Multiple Myeloma Market document provides the same by studying the market and the industry with respect to numerous aspects.
Multiple Myeloma Market report gives explanation about the different segments of the market analysis which is demanded by today’s businesses. Key players are taking actions such as developments, product launches, acquisitions, mergers, joint ventures and competitive analysis in the industry. All the market aspects are estimated and analysed by a team of innovative, enthusiastic and motivated researchers and analysts so that nothing lefts uncovered in the report. Global Multiple Myeloma Market research report, it becomes easy to figure out brand awareness and insight about the brand and product among potential customers.
Data Bridge Market Research analyses that the multiple myeloma market was valued at USD 23.53 billion in 2021 and is expected to reach USD 38.94 billion by 2029, registering a CAGR of 6.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Access Full 350 Pages PDF Report @
https://www.databridgemarketresearch.com/reports/global-multiple-myeloma-market
Multiple myeloma is a type of cancer that develops from malignant plasma cells. Highly unstable aberrant cells migrate through the bloodstream, circulatory, and lymphatic systems to produce malignant tumors. Plasma cells become malignant and increase rapidly, resulting in a tumor known as plasmacytoma, which inhibits the bone marrow from creating healthy blood cells and immunoglobulins. Because myeloma cells develop and multiply, fewer leukocyte, erythrocyte, and platelet cells are formed, resulting in a weakened immune system. Multiple myeloma symptoms include gastrointestinal issues, enlarged organs, renal damage, rapid weight loss, bone pain, and fever. Multiple myeloma is the third most common, following lymphoma and leukaemia as the most frequent blood cancers.
Some of the major players operating in the multiple myeloma market are:
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Ireland)
- Sanofi (France)
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Eli Lilly and Company (US)
- Merck & Co., Inc. (US)
- Allergan (Ireland)
- AstraZeneca (UK)
- AbbVie Inc. (US)
- Johnson & Johnson Private Limited (US)
- Cipla Inc. (US)
- Abbott (US)
- Merck KGaA (Germany)
- LEO Pharma A/S (Denmark)
- Bausch Health Companies Inc. (Canada)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
- Fresenius Kabi AG (Germany)
- Amneal Pharmaceuticals LLC. (US)
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of the top players in the Multiple Myeloma Market.
- Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.
- Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.
- Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Multiple Myeloma Market.
Global Multiple Myeloma Market survey report analyses the general market conditions such as product price, profit, capacity, production, supply, demand, and market growth rate which supports businesses on deciding upon several strategies. Furthermore, big sample sizes have been utilized for the data collection in this business report which suits the necessities of small, medium as well as large size of businesses. The report explains the moves of top market players and brands that range from developments, products launches, acquisitions, mergers, joint ventures, trending innovation and business policies.
Recent Development
- In April 2021, U.S. Food and Drug Administration (FDA) had announced the approval of BCMA-targeted CAR T-Cell Therapy for the treatment of multiple myeloma. The current approval is based in part on the findings of small research that found that idecabtagene vicleucel (ide-cel) reduced tumor size in 72 percent of patients. These effects persisted on average 11 months.
- In June 2021, AbbVie acquired the TeneoOne and its key immunotherapeutic asset for treating multiple myeloma named TNB-383B. TNB-383B is a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's own immune system to target and kill BCMA-expressing tumor cells. AbbVie and TeneoOne announced a strategic partnership in February 2019 to develop and commercialize TNB-383B, a bispecific antibody that targets both BCMA and CD3 and is designed to direct the body's immune system to target and kill BCMA-expressing tumor cells. Based on an interim review of an ongoing Phase I research, AbbVie exercised its acquisition right.
Global Multiple Myeloma Market Scope
The multiple myeloma market is segmented on the basis of type, treatment, diagnosis, symptoms, and dosage forms, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Smouldering Multiple Myeloma
- Active Multiple Myeloma
Treatment
- Medications
- Proteasome Inhibitors
- Bortezomib
- Ixazomib
- Carfilzomib
- Histone Deacetylase (HDAC) Inhibitors
Chemotherapy Drugs
- Bendamustine
- Etoposide
- Doxorubicin
- Liposomal Doxorubicin
- Cyclophosphamide
- Melphalan
- Vincristine
Immunotherapy Drugs
- Lenalidomide
- Thalidomide
- Pomalidomide
Corticosteroids
- Dexamethasone
- Prednisone
Monoclonal antibodies
- Daratumumab
- Isatuximab
- Elotuzumab
- Radiation Therapy
- Stem Cell Transplant
- Others
Diagnosis
· Blood Tests
· Bone Marrow Biopsy
· Urine Tests
· Imaging Tests
· X-ray
· Magnetic resonance imaging (MRI)
· Positron Emission Tomography (PET)
Symptoms
- Bone Pain
- Weight Loss
- Constipation
- Fatigue
- Frequent Infections
- Loss of Appetite
- Confusion
- Numbness in Legs
- Nausea
- Excessive Thirst
- Others
Dosage Forms
- Capsule
- Tablets
- Injections
- Others
Route of Administration
- Oral
- Parenteral
- Intravenous
- Others
- Others
End-Users
- Hospitals
- Specialty Clinics
- Homecare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
- Others
Browse Trending Reports:
Swab Market Trends, Share, Industry Size, Growth, Demand and Opportunities https://www.databridgemarketresearch.com/reports/global-swab-market
Endovenous laser therapy Market Industry Size, Share, Demand and Growth Analysis https://www.databridgemarketresearch.com/reports/global-endovenous-laser-therapy-market
Dental Orthodontics Market Size, Share, Growth, Demand and Emerging Trends https://www.databridgemarketresearch.com/reports/global-dental-orthodontics-market
Cochlear Implants Market Overview, Growth Analysis, Share, Opportunities and Trends https://www.databridgemarketresearch.com/reports/global-cochlear-implants-market
About Data Bridge Market Research:
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.
Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
